glp-1 drugs pharmaceutical companies news 2025 drug exposure GLP-1 Drugs: 2025 Pulse Survey (U.S.) GLP-1 Pipeline Update: August 2025

Plaintiffs allege that these companies failed to adequately warn consumers and prescribing physicians about severe gastrointestinal injuries, vision loss, and other reported complications associated with GLP-1 drugs

Reliable guidelines based on high-quality data from studies assessing a cause-and-effect relationship between GLP-1 RA use and RGC, aspiration, and regurgitation events are therefore more important than ever

GLP-1 drugs help maintain these vital connections

The standard classification of diabetes as type 1, type 2 and gestational diabetes mellitus (GDM) as introduced by the American Diabetes Association (ADA) in 1997 remains the best-accepted and adopted by ADA (4)

What monitoring or follow-up is included, and how do I reach the prescribing clinician if I have concerns